FibroGen Inc. (FGEN), a biopharmaceutical company focused on accelerating the development of novel therapies at the frontiers of cancer, has significant catalysts to watch in the upcoming months.
The company's lead drug candidate is Pamrevlumab, which is in clinical development for the treatment of metastatic pancreatic cancer and locally advanced unresectable pancreatic cancer.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com